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The erbB-2 gene encodes tyrosine kinase receptor p185neu.
Overexpression of erbB-2 plays a key role in tumorigenesis and
the progression of tumors such as breast cancer and ovarian
cancer. Our investigation suggests that the anti-inflammatory
agent N-(4-ethoxyphenol)-2-hydroxy-acid amide (SUCI02)
reversibly represses tyrosine phosphorylation of erbB-2 in a
dose-dependent manner, with half maximal inhibition occurring
at a concentration of 21.05 µmol/L without reduced erbB-2
receptor expression. Activation of mitogen-activated protein
kinase and protein kinase B, downstream molecules of the erbB-
2-mediated signal transduction pathway, was inhibited following
exposure to SUCI02. In contrast, tyrosine phosphorylation of
epidermal growth factor receptor (EGFR) was relatively
unaffected by SUCI02. Proliferation of erbB-2-overexpressing
BT474 cells was inhibited to a greater extent than proliferation of
EGFR-overexpressing A431 cells following exposure to SUCI02.
SUCI02 induced cell cycle arrest in G1 phase with upregulation
of p27 and downregulation of pRb phosphorylation. Systemic
administration of SUCI02 in nude mice resulted in inhibition of
erbB-2 tyrosine kinase phosphorylation of subcutaneous human
breast cancer BT474 xenografts. We conclude that SUCI02
inhibits erbB-2 tyrosine kinase phosphorylation in vitro and
in vivo, shuts down the erbB-2 downstream pathway and
induces cell cycle arrest in G1 phase. These results suggest that
SUCI02 is a potential novel anticancer agent that deserves
further investigation. (Cancer Sci 2006; 97: 84–89)
ErbB-2 is a 185-kDa protein composed of an extracellularligand-binding domain, a short transmembrane domain
and an intracellular domain, which has tyrosine kinase
activity.(1) It has been reported that overexpression of the
erbB-2 receptor plays a key role in pathological processes
such as tumorigenesis and progression, especially in breast
and ovarian cancers, and in other cancers such as gastro-
intestinal, pulmonary and genitourinary neoplasms.(2–6) Breast
cancer is the leading cause of death from cancer among women
in the USA. Amplification of the human proto-oncogene
erbB-2 reportedly occurs in approximately 30% of breast
carcinomas and measurement of the amplification has been
proposed as a useful predictor of disease prognosis.(7) Gene
amplification and the resulting overexpression of the erbB-2
proto-oncogene-encoded p185neu may transform cells by
chronically stimulating the signal transduction pathway.(8)
Overexpression of erbB-2 has also been shown to correlate
with tumor grade, tumor size, lymph node metastasis, survival
and resistance to hormonal therapy and chemotherapy in
breast cancer patients.(9) Epidermal growth factor (EGF) or
heregulin facilitates erbB-2 heterodimerization and
homodimerization with itself or other members of erbB
family, resulting in activation and autophosphorylation of the
protein tyrosine kinase domain.(10) An intact kinase domain is
essential for activation of numerous downstream effectors,
including phospholipase Cγ, phosphatidylinositol-3-kinase
(PI3K)/protein kinase B (AKT) and mitogen-activated
protein kinase (MAPK), with the ultimate cellular response
being DNA synthesis and cell proliferation.(11,12) The known
oncogenic potential mediated by erbB-2 and its high-level
expression in tumor tissues compared with normal cells make
this oncoprotein an ideal target for antitumor therapeutic
approaches. Therapy targeted against erbB-2 has already had
proven clinical outcomes. Genetech developed the
humanized monoclonal antibody Herceptin, which is targeted
against the extracellular domain of erbB-2. The phase III
clinical trials of Herceptin provide evidence that systemic
administration of Herceptin, alone and in combination with
cytotoxic chemotherapy in patients with erbB-2-overexpress-
ing primary tumors, can increase the time to recurrence and
overall response rates in metastatic breast cancer.(13,14) Also,
Gefitinib (ZD1839),(15) is a low molecular weight, synthetic
anilinoquinazoline that selectively inhibits the tyrosine kinase
activity of epidermal growth factor receptor (EGFR). In
patients with advanced non-small cell lung cancer (NSCLC)
who had failed one or two prior chemotherapies, Gefitinib
administered at 250 or 500 mg once daily induced an
objective response in 19% of patients in a double-blind trial
(n = 210).(16) Gefitinib was approved by the Food and Drug
Administration for use as monotherapy for the treatment of
patients with locally advanced or metastatic NSCLC after
failure of both platinum-based and docetaxol chemotherapies.
The success of Herceptin and Gefitinib clearly shows the
therapeutic value of a molecular therapy targeted at erbB-2
and provides much encouragement for the design and
development of other therapies targeted at erbB-2.
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Certain limitations are associated with large molecule
strategies, including poor delivery, poor in vivo stability and
high cost.(17) To overcome these limitations, we have been
actively pursuing small molecule therapeutic strategies targeted
at the erbB-2 receptor-mediated signal transduction pathway.
N-(4-ethoxyphenol)-2-hydroxy-acid amide (SUCI02), which
is as an anti-inflammatory agent, has been used clinically in
China. In the present study, we found that SUCI02 could
inhibit tyrosine phosphorylation of erbB-2 through compre-
hensive screening, block the erbB-2 signaling pathway and
induce G1 arrest in erbB-2-overexpressing breast cancer cells.
Materials and methods
Cell culture and reagents
The human breast cancer cell lines BT474 and A431 were
obtained from the American Type culture collection (Rockville,
MD, USA). BT474 was grown in Dulbecco’s modified
Eagle’s medium (DMEM) medium (Life Technologies,
Grand Island, NY, USA) supplemented with 10% fetal
bovine serum. MDA-MB-453 and A431 cells were cultivated
in RMPI-1640 medium (Life Technologies). Cells were
grown in an incubator at 37°C under 5% CO2 in air. The
erbB-2 antibody was obtained from Calbiochem (San Diego,
CA, USA). Anti-Akt, phospho-Akt, phospho-erbB-2,
phospho-EGFR, MAPK and phospho-MAPK antibodies
were purchased from Cell Signaling (Beverly, MA, USA).
The synthesis of SUCI02 has been described previously.(18)
Its structure is shown in Fig. 1. Drug stock solution was
prepared by dissolving SUCI02 in dimethylsulfoxide
(DMSO). The final concentration of DMSO in SUCI02-
treated cultures was always less than 0.2% (v/v) and did not
contribute to toxicity.
Western blot analysis
Cells treated with SUCI02 were washed twice with
phosphate-buffered saline (PBS) and lysed in 100 µL of lysis
buffer (20 mM Na2PO4 [pH 7.4], 150 mM NaCl, 1% Triton
X-100, 1% aprotinin, 1 mM phenymethysulfonyl fluoride,
10 mg/mL leupeptin, 100 mM NaF and 2 mM Na3VO4).
Lysates were centrifuged at 13 400 g for 10 min and the
supernatant collected. The protein content was determined
using the bicinchoninic acid (BCA) protein assay (Pierce,
Rockford, IL, USA). A total of 40 µg of protein was resolved
by sodium dodecylsulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) using 4–20% gel and transferred
electrophoretically to a nitrocellulose membrane (Amersham,
Piscataway, NJ, USA). The membranes were blotted for
30 min at 25°C with non-fat dry milk (5%) in Tris-buffered
saline-Tween (TBST) (20 mM Tris-HCl [pH 7.4], 150 mM
NaCl, 0.1% Tween), and then incubated with primary
antibodies for 2 h at 25°C. The membranes were washed with
TBST and incubated with horseradish peroxidase-labeled
antimouse or rabbit secondary antibodies for 1 h at 25°C.
After washing with TBST, the bound antibody complex was
detected using an ECL chemiluminescence reagent
(Amersham) and XAR film (Kodak, Pittsburgh, PA, USA) as
described by the manufacturers.
Reversibility and irreversibility of erbB-2 tyrosine kinase 
phosphorylation inhibition
MDA-MB-453 cells overexpressing erbB-2 were plated at a
density of 5 × 105 cells /well in 12-well plates. On the
following day, the regulatory medium was changed to serum-
free medium. Drug stock was added. Following treatment
with 77.8 µM SUCI02 for 30 min, cells were washed twice
with serum-free medium. Serum-free medium (1 mL) was
added and incubated in an incubator at 37°C under 5% CO2
in air for different periods of time. Cells were collected,
lysed and western blot assays were carried out to determine
erbB-2 phosphorylation.
MTT assay
Cells were plated at a density of 2000 cells /well in 96-well
plates. The stock of SUCI02 was diluted with medium, then
added to the wells for the desired final assay concentrations.
After 3 days of exposure to SUCI02, 10 µL of 5 mg/mL
MTT was added to each well and incubated for ≥ 4 h, and the
liquid in the wells was aspirated. DMSO (100 µL) was added
to each well to dissolve the formazam. The absorbance was
detected in a microplate reader at 565 nm wavelength. Cell
viability rates were expressed as a percentage of absorbance
detected in the control wells that were treated with 0.1%
DMSO alone. DMSO controls were not different from cells
in the regulatory growth medium. The IC50 value was
calculated using Bliss software.
Cell cycle analysis
Cells were harvested by trypsinization, washed twice with ice-
cold PBS, resuspended in cold PBS, and fixed with 70%
ethanol. After overnight refrigeration at −20°C and
subsequent rehydration in PBS for 30 min at 4°C, the cell
nuclei were stained for 30 min in the dark with 50 µg/mL
propidium iodide (Sigma, St Louis, MO, USA) containing
125 IU/mL protease-free RNase, both diluted in PBS. Cells
were filtered through a 95-µm pore size nylon mesh, and
a total of 10 000 stained nuclei were analyzed with a
fluorescence-assisted cell sorting (FACS) machine.
Inhibitory effect of SUCI02 on erbB-2 tyrosine kinase 
phosphorylation in vivo in nude mice
Human tumor xenografts were established by 1 × 106 BT474 cells
injected into nude mice subcutaneously. When the volume of
the tumor reached ∼200 mm3, 20 mg/kg SUCI02 was injected
intraperitonealy into mice bearing transplanted BT474 cells
to determine the inhibitory effect of erbB-2 tyrosine kinase
phosphorylation in vivo. The mice were killed, and the tumor
tissues were excised, homogenated and lysed for
determination of erbB-2 phosphorylation using western blot
analysis.Fig. 1. The structure of SUCI02.
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Results
Effect of SUCI02 on tyrosine phosphorylation of erbB-2
To examine the effects of potential of erbB-2 tyrosine kinase
inhibitors, we carried out comprehensive phosphorylation
inhibition. This is because autophosphorylation of erbB-2
increases the velocity of the kinase reaction and only
phosphorylated erbB-2 can provide binding sites for its
substrates (such as phospholipase Cγ, Grb-2 and Shc),
allowing these substrates to bind to the activated receptor.
After comprehensive screening, SUCI02 was found to inhibit
tyrosine phosphorylation of erbB-2. To examine the dose–
effect relationship of inhibition, BT474 cells, which
overexpress p185neu, were treated in serum-free medium with
indicated concentrations of SUCI02 for 1 h. Cells were then
lysed and resolved by SDS-PAGE. The results from western
blot analysis of p185neu protein levels and phosphorylation of
erbB-2 suggested that SUCI02 inhibited phosphorylation of
p185neu significantly in a dose-dependent manner, with an
IC50 value of 21.05 µM in BT474 (Fig. 2). To study the
inhibition of erbB-2 tyrosine phosphorylation by SUCI02 but
not protein expression of erbB-2, protein expression levels of
erbB-2 were detected using the same lysates. The results
showed that the levels of erbB-2 protein were unaffected
following SUCI02 treatment.
Effect of SUCI02 on activation of MAPK and AKT, 
downstream targets of the erbB-2 signaling pathway
Activation of erbB-2 leads to breast cancer cell proliferation,
presumably by inducing activation of the MAPK and PI3K/
AKT pathways. To examine whether SUCI02 can inhibit
activation of MAPK and AKT, BT474 cells were treated with
varying concentrations of SUCI02 for 1 h, and phospho-
MAPK and MAPK were detected with antiphospho-MAPK
and anti-MAPK antibodies. Phospho-Akt and Akt were
detected with antiphospho-AKT and anti-AKT antibodies.
Phospho-MAPK and phospho-Akt are the active forms of
MAPK and Akt, respectively. The results showed that
phospho-MAPK and phospho-Akt levels decreased
significantly after treatment of BT474 cells with SUCI02
(Fig. 3) without reducing total MAPK and Akt. This suggests
that SUCI02 has a potent inhibitory effect on activation of
MAPK and Akt in a dose-dependent manner in erbB-2-
overexpressing cancer cells following SUCI02 treatment.
Selectivity of inhibition of erbB-2 phosphorylation by SUCI02
SUCI02 can inhibit tyrosine phosphorylation of erbB-2. It is
of interest to investigate the selectivity of SUCI02 toward
erbB-2. To examine this issue, human epidermal carcinoma
A431 cell line, which overexpresses EGFR, was treated with
77.8 or 155.6 µM of SUCI02 for 1 h, then analyzed for the
levels of EGFR and phosphorylation of EGFR. As shown in
Fig. 4, SUCI02 had no inhibitory effect on tyrosine
phosphorylation of EGFR and activation of MAPK and AKT
following up to 155.6 µM SUCI02 treatment for 1 h in A431 cells.
Fig. 2. Inhibition of erbB-2 phosphorylation by SUCI02 in BT474
cells. BT474 cells were treated with different concentrations of
SUCI02 for 1 h. Cells were collected and lysed. Western blot analysis
was conducted using antiphospho-erbB-2 and anti-erbB-2
antibodies. The lower panel shows the ratios of phospho-erbB-2
protein relative to erbB-2 protein. This experiment is representative
of three experiments.
Fig. 3. Inhibition of mitogen-activated protein
kinase (MAPK) and AKT phosphorylation by SUCI02
in BT474 cells. BT474 cells were treated with
different concentrations of SUCI02 for 1 h. Cells were
collected and lysed. Western blot analysis was
conducted using antiphospho-MAPK, anti-MAPK,
antiphospho-AKT and anti-AKT antibodies. This
experiment is a representative of two experiments.
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Reversible inhibition of erbB-2 tyrosine kinase 
phosphorylation by SUCI02
The results shown above indicate that SUCI02 inhibits
tyrosine phosphorylation of erbB-2. To investigate whether
inhibition of tyrosine phosphorylation of erbB-2 by SUCI02
is reversible, MDA-MB-453 cells treated with 38.9 µmol/L
SUCI02 in serum-free medium for 30 min were washed
twice with serum-free medium and then incubated for either
30 min or 8 h. Tyrosine phosphorylation of erbB-2 was then
detected. The results in Fig. 5 show that inhibition of erbB-2
phosphorylation was recovered 30 min after SUCI02 was
washed out. This indicates that inhibition of erbB-2
phosphorylation is reversible.
Effect of SUCI02 on proliferation of human breast cancer cells
The results described above suggest that SUCI02 inhibits
tyrosine phosphorylation of p185neu in a breast cancer cell line
overexpressing erbB-2. However, it was not known whether
SUCI02 could inhibit cell growth preferentially in breast
cancer cells that overexpress p185neu. In order to examine this
issue, BT474 and A431 were used. The results shown in
Fig. 6 indicate that SUCI02 has a greater inhibitory effect on
BT474 cells compared to A431 cells. Their IC50 values were
12.8 µM and 43.9 µM, respectively. This indicates that SUCI02
inhibits growth of cells overexpressing erbB-2 preferentially.
SUCI02 halts the cell cycle in BT474 cells
The effects on cell cycle were studied following SUCI02
treatment in BT474 cells. Cell cycle distribution was detected
at various concentrations of SUCI02 (0, 4.9, 9.7, 19.4 and
38.9 µM). As shown in Table 1, the percentages of cells in G1
phase were 56.4, 62.1, 66.3, 71.5 and 78.7%, respectively.
Also, the results from western blot analysis showed that p27
protein expression was upregulated and hyperphosphorylated
Rb decreased after SUCI02 treatment  (Figs 7 and 8).
Inhibition of erbB-2 phosphorylation by SUCI02 in vivo
To investigate the in vivo effect of SUCI02 on erbB-2
phosphorylation under systemic administration in animals,
Fig. 4. Effect of SUCI02 on epidermal growth factor receptor
(EGFR), protein kinase B (AKT) and mitogen-activated protein kinase
(MAPK) phosphorylation. A431 cells were treated with different
concentrations of SUCI02 for 1 h. Cells were collected and lysed.
Western blot analysis was conducted using anti-EGFR, antiphospho-
AKT, antiphospho-MAPK and antiphospho-EGFR antibodies. This
experiment is representative of two experiments.
Fig. 5. Reversible inhibition of erbB-2 phosphorylation by SUCI02.
MDA-MB-453 cells were treated with 0.2% dimethylsulfoxide (A,E),
or 38.9 µmol/L SUCI02 (B,C,D) for 30 min, then washed with
medium and incubated for 30 min (C) or 8 h (D). Western blot
analysis was carried out using antiphospho-erbB-2 or anti-erbB-2
antibodies. This experiment was repeated twice.
Fig. 6. Growth inhibition of SUCI02 on cancer cell lines. BT474 and
A431 cells were plated at a density of 2000 cells /well in 96-well
plates. The stock of SUCI02 was added to wells. In the serum-free
treatments, the cells were incubated for 3 days. Cell viability was
determined using the MTT assay is expressed as cell viability
rate ± SE (n = 4).




0 4.9 9.7 19.4 38.9
G0/G1 56.68 61.21 60.81 64.93 78.91
S 41.1 34.67 36.42 30.67 18.38
G2/M 2.22 4.12 2.77 4.40 2.70
Fig. 7. Effect of SUCI02 on p27 protein levels in BT474 cells. BT474
cells were treated with different concentrations of SUCI02 for 24 h.
Cells were collected and lysed. Western blot analysis was conducted
using anti-p27 and anti-hsp70 antibodies. This experiment was
repeated twice.
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the BT474 xenograft model, which forms progressive tumors
in nude mice, was utilized. The mice bearing BT474
xenografts was treated with SUCI02 at 20 mg/kg, twice daily
for 2 days. Tumors were excised at 24 h after treatment, and
homogenates were prepared for determining the levels of
phosphorylated erbB-2 by western blot analysis. Treatment
with SUCI02 suppressed erbB-2 phosphorylation markedly
(Fig. 9). It was of note that SUCI02 had no effect on total
erbB-2 protein expression.
Discussion
Overexpression of erbB-2, which is a member of the EGFR
family, correlates to a poor prognosis and decreased survival
rate in patients with breast cancer, ovarian cancer and other
cancers.(3) Activation of erbB-2 by EGF-like ligand results in
its receptor tyrosine kinase phosphorylation. Phosphorylated
erbB-2 receptor provides binding sites for Src homology (SH)-
2 domain-containing proteins, including the adaptor proteins
Grb-2 and Shc. In addition to the SH-2 domain, Grb-2 binds
small nucleotide exchange proteins such as SOS through its
SH-3 domain, and then activates Ras through exchanging
GTP for GDP on Ras. Activated Ras binds to and facilitates
Raf activation. Activated Raf stimulates mitogen-activated
protein kinase kinase kinase (MEKK) activity, which, in turn,
activates the MAPK pathway. The MAPK pathway is
important for cell proliferation, transformation and differentiation.
Blocking MAPK activity can inhibit cancer cell growth
in vitro and in vivo.(19,20) The same results could be observed
under inhibition of Ras by a farnesyl : protein transferase
inhibitor.(21) ErbB-2 is also critical to activation of the PI3K
pathway by heterodimerization with erbB-3, which is the only
erbB-2 receptor able to recruit the p85 subunits of PI3K.(12)
ErbB-2 is a potent target for cancer treatment. In the
present study, we found that SUCI02 inhibited tyrosine
phosphorylation of erbB-2. ErbB-2 tyrosine phosphorylation
was inhibited by SUCI02 in erbB-2-overexpressing BT474
cells, but expression of the erbB-2 protein was unaffected.
This indicates that inhibition of phosphorylation of erbB-2 is
not via reduced erbB-2 expression. SUCI02 has no inhibitory
effect on tyrosine phosphorylation of EGFR under the same
concentrations of SUCI02. This indicates that SUCI02 can
selectively inhibit erbB-2 phosphorylation.
Overexpression of erbB-2 activates the MAPK and AKT
pathways associated with proliferation and survival of cells
overexpressing erbB-2. Both MAPK and AKT are down-
stream targets of erbB-2. SUCI02 can inhibit tyrosine phos-
phorylation of erbB-2. It was predicted that MAPK and AKT
activation should also be inhibited by SUCI02. Our results
indicate that phospho-MAPK and phospho-Akt levels were
decreased markedly, but total MAPK and Akt levels were not
decreased. These results indicate that SUCI02 can inhibit
activation of MAPK and Akt.
SUCI02 inhibits tyrosine phosphorylation of erbB-2,
thereby inhibiting the MAPK and PI3K/Akt pathways. Inhi-
bition of BT474 cell and A431 cell proliferation by SUCI02
was investigated. The results show that SUCI02 inhibits
BT474 cell growth significantly. By comparison, growth
inhibition of A431 cells by SUCI02 was weaker although
SUCI02 could inhibit A431 cell growth at high concentra-
tions. It is possible that SUCI02 has other targets or that
A431 cells have a low level of erbB-2 expression. SUCI02
did not influence EGFR phosphorylation in A431 cells.
Therefore, it might not influence the dissociation of ligands
such EGF and transforming growth factor (TGF)-α. How-
ever, it could influence the dimerization between human epi-
dermal growth factor receptor (HER)2 and other HER
proteins or directly inhibit the tyrosine kinase activity of
erbB-2. We did not carry out in vitro kinase assays, so it is
not known whether SUCI02 directly inhibits the protein tyro-
sine kinase of erbB-2.
SUCI02 can induce cell cycle arrest in G1 phase. In order
to elucidate the molecules involved in G1 arrest following
SUCI02 treatment in BT474 cells, p27 protein expression
and hyperphosphorylated Rb were detected after BT474 cells
were treated with various concentrations of SUCI02. The
results show that SUCI02 induces p27 upregulation and
decreases phosphorylated Rb in a dose-dependent manner.
P27 is a member of the KIP family, which was originally dis-
covered as a cyclin-dependent kinase (Cdk) inhibitor induced
by extracellular antimitogenic signals.(22,23) It can inhibit
cdk4/6 activity and its overexpression halts the cell cycle in
G1 phase. Cdks can phosphorylate Rb, then E2F which is a
transcription factor is released. E2F can promote cell cycle
progression. Induction of p27 is usually regulated post-
transcriptionally. The stabilization of phosphorylated p27 is
decreased through the ubiquitin degradation system. Upregu-
lation of p27 following SUCI02 treatment in BT474 cells
could cause an increase in p27 stabilization and a decrease in
phosphorylation of p27. This may be because inhibition of
Fig. 8. Effect of SUCI02 on the levels of pRb protein
phosphorylation in BT474 cells. BT474 cells were treated with
different concentrations of SUCI02 for 24 h. Cells were collected and
lysed. Western blot analysis was conducted using anti-pRb and anti-
hsp70 antibodies. This experiment is representative of two
experiments.
Fig. 9. Inhibition of erbB-2 phosphorylation by SUCI02 in vivo. The
nude mice bearing BT474 xenografts were treated with 20 mg/kg
SUCI02 twice daily for 2 days. The mice were killed, and the tumors
were excised and homogenated. Western blot analysis was
conducted using anti-erbB-2 and anti-phospho-erbB-2 antibodies.
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Akt activation by SUCI02 results in a decrease in p27 phos-
phorylation and accumulation of p27, and eventually arrests
the cell cycle in G1 phase, inhibiting cell growth.
SUCI02 can also inhibit erbB-2 tyrosine kinase phosphor-
ylation in vivo. Therefore, SUCI02 should be able to inhibit
erbB-2-overexpressing cancer cell growth. Taken together,
SUCI02 inhibits tyrosine phosphorylation of erbB-2 selectively,
shuts down the erbB-2 signaling pathway, arrests the cell cycle
in G1 phase and inhibits growth of erbB-2-overexpressing
cancer cells. Our experiments suggest that SUCI02 is a potential
novel anticancer agent that deserves further investigation.
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